Peter Fedichev is the CSO and Co-founder of GERO (formerly Quantum Pharmaceuticals), a drug discovery company creating first-in-class small molecule therapeutics using proprietary, industry-leading molecular modeling methods and systems in the sphere of biology technologies.Dr. Fedichev’s work for GERO included the application of sophisticated physics to rational drug discovery. As GERO’s drug discovery efforts progressed, his focus shifted from the drug discovery of known targets into the new field of complex diseases, in which the targets were unknown. This led the company into aging research.Dr. Fedichev studied at MIPT (Moscow Institute of Physics and Technology) and did his graduate work at Kurchatov Institute (theoretical atomic and molecular physics). He received his PhD from the University of Amsterdam in theoretical condensed matter physics. He worked for FOM Institute Amolf and the University of Innsbruck before co-founding Quantum Pharmaceuticals.
Designing new drugs against aging and age-related diseases